FDA Draft Aims to Slash Animal Tests for New Cancer Drugs
Published Date: 6/1/2026
Notice
Summary
The FDA is rolling out a new draft guide to help cancer drug makers speed up safety testing for biologic and conjugated medicines. This plan cuts down on extra animal testing and uses smarter methods learned during the COVID-19 pandemic. Drug developers should send their feedback by July 31, 2026, to shape the final rules and save time and money in bringing new cancer treatments to patients.
Analyzed Economic Effects
5 provisions identified: 4 benefits, 1 costs, 0 mixed.
Faster safety testing for cancer drugs
The FDA published a draft guidance to help sponsors of biologic and conjugated oncology products streamline nonclinical safety testing so drug development can move faster and avoid unnecessary studies. The draft is open for comments and stakeholders should submit feedback by July 31, 2026.
Reduced use of animals and primates
The draft guidance recommends approaches to avoid unnecessary animal use and to reduce use of non-human primates in nonclinical safety studies, using practices developed during the COVID-19 pandemic.
Primary focus on 3‑month toxicology
When finalized, the guidance will give recommendations for general toxicology studies with a primary focus on 3-month toxicology studies for certain oncology biologic and conjugated products.
Guidance excludes impurities and excipients
The draft guidance does not address nonclinical safety assessments for impurities or excipients, so sponsors must rely on other guidance or regulations for those elements of product development.
Opportunity to comment on costs
FDA will consider comments on costs or cost savings the guidance may generate, consistent with Executive Order 14192; submit comments by July 31, 2026 to ensure consideration before the final guidance.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10899 — Medical Devices; Dental Devices; Classification of the Intraoral Cooling Device
The FDA is officially putting the intraoral cooling device into class II, meaning it has special safety rules but fewer hurdles than the highest-risk devices. This change helps make sure the device is safe and effective while making it easier for patients to get this cool tech. The new classification is effective June 1, 2026, but it’s been in place since October 14, 2022, so manufacturers can plan ahead without extra costs.
2026-10904 — Medical Devices; Gastroenterology-Urology Devices; Classification of the Orally Ingested Transient Device for Constipation
The FDA is officially putting the new swallowed device for constipation into a safer, easier-to-manage category called Class II. This change helps make sure the device works well and is safe, while also speeding up patient access to this cool innovation by cutting down red tape. The new rules took effect June 1, 2026, and could save companies time and money getting their devices approved.
2026-10907 — Medical Devices; Anesthesiology Devices; Classification of the Real-Time Ultrasound Anatomy Visualization and Labeling Device for Ultrasound Guided Regional Anesthesia
The FDA is officially classifying a new ultrasound device that helps doctors see and label anatomy in real-time during regional anesthesia as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change makes it easier and faster for patients to get access to this helpful technology without compromising safety. The new classification is effective June 1, 2026, and could save time and money for device makers and hospitals.
2026-10905 — Medical Devices; Anesthesiology Devices; Classification of the Adjunctive Pain Measurement Device for Anesthesiology
The FDA is officially putting the adjunctive pain measurement device for anesthesiology into Class II, meaning it now has special safety rules but fewer hurdles than the strictest category. This change helps make sure the device is safe and effective while making it easier for patients to get new, helpful technology. The new classification is effective June 1, 2026, and could speed up innovation without extra costs for makers.
2026-10894 — Medical Devices; Ear, Nose, and Throat Devices; Classification of the Oropharyngeal Electrical Stimulator
The FDA is officially putting the oropharyngeal electrical stimulator into Class II, meaning it has special safety rules but is easier to get to patients. This change helps make sure the device is safe and effective while cutting down on red tape, so more people can benefit from this cool tech. The new rules took effect on June 1, 2026, but the classification has been in place since September 2022.
2026-10898 — Medical Devices; Hematology and Pathology Devices; Classification of the Von Willebrand Factor Assay
The FDA is officially putting the von Willebrand factor assay into Class II, meaning it now has special safety rules but fewer red tape hurdles. This change helps labs and patients get access to this important blood test faster and safer, starting June 1, 2026. If you make or use these devices, expect smoother approvals and no big cost jumps.
Previous / Next Documents
Previous: 2026-10868 — Designation of New Grantee; Foreign-Trade Zone 181; Akron/Canton, Ohio
The Foreign-Trade Zone 181 in Akron/Canton, Ohio, has a new boss! The Development Finance Authority of Summit County is now in charge, taking over from the Northeast Ohio Joint Office of Economic Development. This change is official as of May 2026 and keeps the zone running smoothly to help local businesses trade smarter and faster.
Next: 2026-10874 — Sunshine Act Meetings
The SEC is holding a closed meeting on June 4, 2026, to discuss important legal and enforcement actions. This affects SEC commissioners and select staff, with no public access or direct cost changes. If anything about the meeting changes, updates will be posted online, keeping everyone in the loop.